Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-01

AUTHORS

Robin L. Jones, Gary Mo, John R. Baldwin, Patrick M. Peterson, Robert L. Ilaria, Ilaria Conti, Damien M. Cronier, William D. Tap

ABSTRACT

PURPOSE: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure-response relationship for progression-free survival (PFS), overall survival (OS), and safety. METHODS: PFS and OS data from the 133 patients enrolled in the phase 2 study were analysed using time-to-event modelling. The effect of olaratumab on PFS/OS was explored using the trough serum concentration after cycle 1 (Cmin1) and the average concentration throughout treatment (Cavg). The rate of treatment-emergent adverse events (TEAEs) was compared across olaratumab exposure quartiles. RESULTS: PFS and OS were described by models with an exponential hazard function and inhibitory EMAX functions to describe the effect of olaratumab, regardless of the PK endpoint. The olaratumab EC50s for PFS (ECmin150 = 82.0 µg/mL, ECavg50 = 179 µg/mL) and OS (ECmin150 = 66.1 µg/mL, ECavg50 = 134 µg/mL) corresponded to the median and 25th percentile of Cmin1/Cavg in the study, respectively. Maximum predicted improvement in the hazard ratio for OS and PFS was approximately 75% and 60%, respectively. There was no change in the rate of TEAEs with increasing olaratumab serum levels. CONCLUSIONS: PFS/OS benefits occurred without a rate change in TEAEs across quartiles. Maximum benefit in OS was achieved in the upper three quartiles and a potential of early disease progression in the lower quartile of olaratumab serum exposure. These results prompted a loading dose strategy in the ongoing phase 3 STS trial. More... »

PAGES

191-199

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-018-3723-4

DOI

http://dx.doi.org/10.1007/s00280-018-3723-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109785888

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30406840


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "University of Washington and Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, 98109, Seattle, WA, USA", 
            "Royal Marsden Hospital and Institute of Cancer Research, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Robin L.", 
        "id": "sg:person.01110361365.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mo", 
        "givenName": "Gary", 
        "id": "sg:person.010606122673.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010606122673.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baldwin", 
        "givenName": "John R.", 
        "id": "sg:person.011403503273.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011403503273.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peterson", 
        "givenName": "Patrick M.", 
        "id": "sg:person.01006007223.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006007223.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Celgene (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418722.a", 
          "name": [
            "Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA", 
            "Celgene, Summit, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ilaria", 
        "givenName": "Robert L.", 
        "id": "sg:person.0773461510.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773461510.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA", 
            "EMD Serono Research & Development Institute, Billerica, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Conti", 
        "givenName": "Ilaria", 
        "id": "sg:person.015517404425.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015517404425.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418786.4", 
          "name": [
            "Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor Sunninghill Road, GU20 6PH, Windlesham, Surrey, UK", 
            "Merck Serono Ltd, Feltham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cronier", 
        "givenName": "Damien M.", 
        "id": "sg:person.01202643552.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643552.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 1275 York Ave, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tap", 
        "givenName": "William D.", 
        "id": "sg:person.0732525354.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732525354.50"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s1470-2045(00)00016-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006755774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)30587-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009229330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)01283-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014338125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.7717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014449747"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.67.6684", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031855537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.62.4734", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035914578"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)60651-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040046880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270012445206", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040497500"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-13-385", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041401483", 
          "https://doi.org/10.1186/1471-2407-13-385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70063-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041916369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.10.4117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044406195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077021719", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-017-0562-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086046138", 
          "https://doi.org/10.1007/s40262-017-0562-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-017-0562-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086046138", 
          "https://doi.org/10.1007/s40262-017-0562-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30381-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086140203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30622-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091478089"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-01", 
    "datePublishedReg": "2019-01-01", 
    "description": "PURPOSE: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFR\u03b1. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure-response relationship for progression-free survival (PFS), overall survival (OS), and safety.\nMETHODS: PFS and OS data from the 133 patients enrolled in the phase 2 study were analysed using time-to-event modelling. The effect of olaratumab on PFS/OS was explored using the trough serum concentration after cycle 1 (Cmin1) and the average concentration throughout treatment (Cavg). The rate of treatment-emergent adverse events (TEAEs) was compared across olaratumab exposure quartiles.\nRESULTS: PFS and OS were described by models with an exponential hazard function and inhibitory EMAX functions to describe the effect of olaratumab, regardless of the PK endpoint. The olaratumab EC50s for PFS (ECmin150\u2009=\u200982.0\u00a0\u00b5g/mL, ECavg50\u2009=\u2009179\u00a0\u00b5g/mL) and OS (ECmin150\u2009=\u200966.1\u00a0\u00b5g/mL, ECavg50\u2009=\u2009134\u00a0\u00b5g/mL) corresponded to the median and 25th percentile of Cmin1/Cavg in the study, respectively. Maximum predicted improvement in the hazard ratio for OS and PFS was approximately 75% and 60%, respectively. There was no change in the rate of TEAEs with increasing olaratumab serum levels.\nCONCLUSIONS: PFS/OS benefits occurred without a rate change in TEAEs across quartiles. Maximum benefit in OS was achieved in the upper three quartiles and a potential of early disease progression in the lower quartile of olaratumab serum exposure. These results prompted a loading dose strategy in the ongoing phase 3 STS trial.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-018-3723-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "83"
      }
    ], 
    "name": "Exposure\u2013response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma", 
    "pagination": "191-199", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ecf248a63b1ccae3752105caaa9a479aeb6cda424665dc20faa85b53a61d5181"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30406840"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-018-3723-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109785888"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-018-3723-4", 
      "https://app.dimensions.ai/details/publication/pub.1109785888"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000354_0000000354/records_11734_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00280-018-3723-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3723-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3723-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3723-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-018-3723-4'


 

This table displays all metadata directly associated to this object as RDF triples.

180 TRIPLES      21 PREDICATES      44 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-018-3723-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N7a3d5acc71004fb193133c427944182a
4 schema:citation sg:pub.10.1007/s40262-017-0562-0
5 sg:pub.10.1186/1471-2407-13-385
6 https://app.dimensions.ai/details/publication/pub.1077021719
7 https://doi.org/10.1016/s0140-6736(12)60651-5
8 https://doi.org/10.1016/s0140-6736(15)01283-0
9 https://doi.org/10.1016/s0140-6736(16)30587-6
10 https://doi.org/10.1016/s1470-2045(00)00016-4
11 https://doi.org/10.1016/s1470-2045(14)70063-4
12 https://doi.org/10.1016/s1470-2045(17)30381-9
13 https://doi.org/10.1016/s1470-2045(17)30622-8
14 https://doi.org/10.1177/0091270012445206
15 https://doi.org/10.1200/jco.2006.09.7717
16 https://doi.org/10.1200/jco.2006.10.4117
17 https://doi.org/10.1200/jco.2015.62.4734
18 https://doi.org/10.1200/jco.2016.67.6684
19 schema:datePublished 2019-01
20 schema:datePublishedReg 2019-01-01
21 schema:description PURPOSE: Olaratumab is a recombinant human IgG1 monoclonal antibody against PGDFRα. Olaratumab plus doxorubicin improved survivalversus doxorubicin in an open-label, randomised phase 2 soft tissue sarcoma (STS) trial. We characterised the olaratumab exposure-response relationship for progression-free survival (PFS), overall survival (OS), and safety. METHODS: PFS and OS data from the 133 patients enrolled in the phase 2 study were analysed using time-to-event modelling. The effect of olaratumab on PFS/OS was explored using the trough serum concentration after cycle 1 (Cmin1) and the average concentration throughout treatment (Cavg). The rate of treatment-emergent adverse events (TEAEs) was compared across olaratumab exposure quartiles. RESULTS: PFS and OS were described by models with an exponential hazard function and inhibitory EMAX functions to describe the effect of olaratumab, regardless of the PK endpoint. The olaratumab EC50s for PFS (ECmin150 = 82.0 µg/mL, ECavg50 = 179 µg/mL) and OS (ECmin150 = 66.1 µg/mL, ECavg50 = 134 µg/mL) corresponded to the median and 25th percentile of Cmin1/Cavg in the study, respectively. Maximum predicted improvement in the hazard ratio for OS and PFS was approximately 75% and 60%, respectively. There was no change in the rate of TEAEs with increasing olaratumab serum levels. CONCLUSIONS: PFS/OS benefits occurred without a rate change in TEAEs across quartiles. Maximum benefit in OS was achieved in the upper three quartiles and a potential of early disease progression in the lower quartile of olaratumab serum exposure. These results prompted a loading dose strategy in the ongoing phase 3 STS trial.
22 schema:genre research_article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf N2d50b596194a4655830330879ebabe29
26 Nb8404ea75eaf4f41be74759b49d1ce59
27 sg:journal.1088364
28 schema:name Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
29 schema:pagination 191-199
30 schema:productId N368e58f4572b4206952e67d0fa9e9bcb
31 N518e162722c6450ea0fa6e70934019c4
32 N5506ed9b64c84c36a26ed325e8aabe68
33 N58418a91332245a383492be120b0dced
34 Nae3eb337864647c086a9256a1f66e74c
35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109785888
36 https://doi.org/10.1007/s00280-018-3723-4
37 schema:sdDatePublished 2019-04-11T11:22
38 schema:sdLicense https://scigraph.springernature.com/explorer/license/
39 schema:sdPublisher N2a728be9f0d144ce9cf7451a9ea55516
40 schema:url https://link.springer.com/10.1007%2Fs00280-018-3723-4
41 sgo:license sg:explorer/license/
42 sgo:sdDataset articles
43 rdf:type schema:ScholarlyArticle
44 N00ddb77763fa44a5a4abe541ef6e5254 rdf:first sg:person.01006007223.55
45 rdf:rest N08a3596c79be448b86259a1201988e8d
46 N08a3596c79be448b86259a1201988e8d rdf:first sg:person.0773461510.58
47 rdf:rest N6809f876406e461883a0873100cb748b
48 N14e67f51c3874876aab7d7c082614f87 rdf:first sg:person.01202643552.61
49 rdf:rest N5d14b691b17642cbbcbc90cbd185eafb
50 N2a728be9f0d144ce9cf7451a9ea55516 schema:name Springer Nature - SN SciGraph project
51 rdf:type schema:Organization
52 N2d50b596194a4655830330879ebabe29 schema:volumeNumber 83
53 rdf:type schema:PublicationVolume
54 N368e58f4572b4206952e67d0fa9e9bcb schema:name readcube_id
55 schema:value ecf248a63b1ccae3752105caaa9a479aeb6cda424665dc20faa85b53a61d5181
56 rdf:type schema:PropertyValue
57 N4f22afe9f0a14aa493be880ef58180df rdf:first sg:person.010606122673.05
58 rdf:rest Nd882473f7ff9423caee69fa060f5514d
59 N518e162722c6450ea0fa6e70934019c4 schema:name nlm_unique_id
60 schema:value 7806519
61 rdf:type schema:PropertyValue
62 N5506ed9b64c84c36a26ed325e8aabe68 schema:name pubmed_id
63 schema:value 30406840
64 rdf:type schema:PropertyValue
65 N58418a91332245a383492be120b0dced schema:name doi
66 schema:value 10.1007/s00280-018-3723-4
67 rdf:type schema:PropertyValue
68 N5d14b691b17642cbbcbc90cbd185eafb rdf:first sg:person.0732525354.50
69 rdf:rest rdf:nil
70 N6809f876406e461883a0873100cb748b rdf:first sg:person.015517404425.93
71 rdf:rest N14e67f51c3874876aab7d7c082614f87
72 N7a3d5acc71004fb193133c427944182a rdf:first sg:person.01110361365.31
73 rdf:rest N4f22afe9f0a14aa493be880ef58180df
74 Nae3eb337864647c086a9256a1f66e74c schema:name dimensions_id
75 schema:value pub.1109785888
76 rdf:type schema:PropertyValue
77 Nb8404ea75eaf4f41be74759b49d1ce59 schema:issueNumber 1
78 rdf:type schema:PublicationIssue
79 Nd882473f7ff9423caee69fa060f5514d rdf:first sg:person.011403503273.84
80 rdf:rest N00ddb77763fa44a5a4abe541ef6e5254
81 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
82 schema:name Medical and Health Sciences
83 rdf:type schema:DefinedTerm
84 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
85 schema:name Clinical Sciences
86 rdf:type schema:DefinedTerm
87 sg:journal.1088364 schema:issn 0344-5704
88 1432-0843
89 schema:name Cancer Chemotherapy and Pharmacology
90 rdf:type schema:Periodical
91 sg:person.01006007223.55 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
92 schema:familyName Peterson
93 schema:givenName Patrick M.
94 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006007223.55
95 rdf:type schema:Person
96 sg:person.010606122673.05 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
97 schema:familyName Mo
98 schema:givenName Gary
99 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010606122673.05
100 rdf:type schema:Person
101 sg:person.01110361365.31 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
102 schema:familyName Jones
103 schema:givenName Robin L.
104 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31
105 rdf:type schema:Person
106 sg:person.011403503273.84 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
107 schema:familyName Baldwin
108 schema:givenName John R.
109 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011403503273.84
110 rdf:type schema:Person
111 sg:person.01202643552.61 schema:affiliation https://www.grid.ac/institutes/grid.418786.4
112 schema:familyName Cronier
113 schema:givenName Damien M.
114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643552.61
115 rdf:type schema:Person
116 sg:person.015517404425.93 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
117 schema:familyName Conti
118 schema:givenName Ilaria
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015517404425.93
120 rdf:type schema:Person
121 sg:person.0732525354.50 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
122 schema:familyName Tap
123 schema:givenName William D.
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732525354.50
125 rdf:type schema:Person
126 sg:person.0773461510.58 schema:affiliation https://www.grid.ac/institutes/grid.418722.a
127 schema:familyName Ilaria
128 schema:givenName Robert L.
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773461510.58
130 rdf:type schema:Person
131 sg:pub.10.1007/s40262-017-0562-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086046138
132 https://doi.org/10.1007/s40262-017-0562-0
133 rdf:type schema:CreativeWork
134 sg:pub.10.1186/1471-2407-13-385 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041401483
135 https://doi.org/10.1186/1471-2407-13-385
136 rdf:type schema:CreativeWork
137 https://app.dimensions.ai/details/publication/pub.1077021719 schema:CreativeWork
138 https://doi.org/10.1016/s0140-6736(12)60651-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040046880
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1016/s0140-6736(15)01283-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014338125
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1016/s0140-6736(16)30587-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009229330
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1016/s1470-2045(00)00016-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006755774
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1016/s1470-2045(14)70063-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041916369
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1016/s1470-2045(17)30381-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086140203
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/s1470-2045(17)30622-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091478089
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1177/0091270012445206 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040497500
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1200/jco.2006.09.7717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014449747
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1200/jco.2006.10.4117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044406195
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1200/jco.2015.62.4734 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035914578
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1200/jco.2016.67.6684 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031855537
161 rdf:type schema:CreativeWork
162 https://www.grid.ac/institutes/grid.18886.3f schema:alternateName Institute of Cancer Research
163 schema:name Royal Marsden Hospital and Institute of Cancer Research, London, UK
164 University of Washington and Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, 98109, Seattle, WA, USA
165 rdf:type schema:Organization
166 https://www.grid.ac/institutes/grid.417540.3 schema:alternateName Eli Lilly (United States)
167 schema:name EMD Serono Research & Development Institute, Billerica, MA, USA
168 Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA
169 rdf:type schema:Organization
170 https://www.grid.ac/institutes/grid.418722.a schema:alternateName Celgene (United States)
171 schema:name Celgene, Summit, NJ, USA
172 Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA
173 rdf:type schema:Organization
174 https://www.grid.ac/institutes/grid.418786.4 schema:alternateName Eli Lilly (United Kingdom)
175 schema:name Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor Sunninghill Road, GU20 6PH, Windlesham, Surrey, UK
176 Merck Serono Ltd, Feltham, UK
177 rdf:type schema:Organization
178 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
179 schema:name Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 1275 York Ave, 10065, New York, NY, USA
180 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...